Featured Research

from universities, journals, and other organizations

Minority disparities evident in prostate cancer survival rate, study shows

Date:
March 20, 2014
Source:
Mayo Clinic
Summary:
African-American men are at increased risk for poorer survival rate following prostate cancer treatment compared to other minority groups, a new study found, which reviewed data on more than 290,000 men with prostate cancer from the past 20 years. "Theoretically, if all clinical and demographic variables are the same and people have similar access to treatment, they should have the equal survival rates," says a urologist and co-author of the report. "We found that is not the case."

A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk for poorer survival rate following prostate cancer treatment compared to other minority groups. The study was recently published in Mayo Clinic Proceedings.

Researchers say that it has long been known that the survival rates of African-American men are less than Caucasian men but there was less information about other minorities such as Hispanics and Asians. Using data from the National Cancer Institute, the researchers used consistent clinical parameters among the groups and found that the survival rates for Hispanics and Asians were about the same as Caucasian.

"Theoretically, if all clinical and demographic variables are the same and people have similar access to treatment, they should have the equal survival rates," says Mark D. Tyson, II, M.D, a urologist at Mayo Clinic in Arizona. "We found that is not the case."

Dr. Tyson said the research team believes that the disparity can be attributed to post treatment factors. He said the next phase of the research will examine what post treatment factors contribute to the survival rate. He said that it is important for both physicians and patients to know that the disparity exists and there could be a variety of reasons why.

"What we do know is that with all other things being equal there is still this disparity… and the study really points to that post treatment period," Dr. Tyson says. "The message that patients and clinicians can take away from this study is that patients need to be followed closely particularly if they are of African-American descent."


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mark D. Tyson, Erik P. Castle. Racial Disparities in Survival for Patients With Clinically Localized Prostate Cancer Adjusted for Treatment Effects. Mayo Clinic Proceedings, 2014; 89 (3): 300 DOI: 10.1016/j.mayocp.2013.11.001

Cite This Page:

Mayo Clinic. "Minority disparities evident in prostate cancer survival rate, study shows." ScienceDaily. ScienceDaily, 20 March 2014. <www.sciencedaily.com/releases/2014/03/140320100605.htm>.
Mayo Clinic. (2014, March 20). Minority disparities evident in prostate cancer survival rate, study shows. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/03/140320100605.htm
Mayo Clinic. "Minority disparities evident in prostate cancer survival rate, study shows." ScienceDaily. www.sciencedaily.com/releases/2014/03/140320100605.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins